Standout Papers
- Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. (1996)
Citation Impact
Citing Papers
Directed evolution of the tryptophan synthase β-subunit for stand-alone function recapitulates allosteric activation
2015 StandoutNobel
Multidimensional traction force microscopy reveals out-of-plane rotational moments about focal adhesions
2012 StandoutNobel
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
2006 Standout
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Keeping G Proteins at Bay: A Complex Between G Protein-Coupled Receptor Kinase 2 and Gßγ
2003 StandoutScienceNobel
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
2002
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
2008
Hallmarks of Cancer: The Next Generation
2011 Standout
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
1997
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions
2000
The Shurosporine Producing Strain Streptomyces longisporoflavus Produces Metabolites Related to K-252a. Proposal for Biosynthetic Intermediates of K-252a.
1996
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
2003
Regulation of cell death by the Abl tyrosine kinase
2000
Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110
1999
A facile process for the asymmetric synthesis of β-trifluoromethylated β-amino ketones via addition of ketone enolates to sulfinylimine
2011
Adhesion-mediated mechanosensitivity: a time to experiment, and a time to theorize
2006
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
2010
Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
2000
Effect of Imatinib Mesylate on Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells
2003
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
The Drosophila Circadian Network Is a Seasonal Timer
2007 StandoutNobel
Protein kinase inhibition of clinically important staurosporine analogues
2010
Bcr–Abl variants: biological and clinical aspects
2002
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine
2009 StandoutNobel
Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases
2008
A Nitro Analogue of Staurosporine and Other Minor Metabolites Produced by a Streptomyces longisporoflavus Strain.
1995
Asymmetric Synthesis of Selectively Protected Amino Sugars and Derivatives by a Direct Organocatalytic Mannich Reaction
2005
Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations
2009
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
2006
Heat Sensitization in Skin and Muscle Nociceptors Expressing Distinct Combinations of TRPV1 and TRPV2 Protein
2007
Efficient palladium-catalyzed synthesis of 3-aryl-4-indolylmaleimides
2008
Tyrosine kinases as targets in cancer therapy – successes and failures
2003
Structural Basis for the Recognition of c-Src by Its Inactivator Csk
2008
Inhibition of Cell Migration by Abl Family Tyrosine Kinases through Uncoupling of Crk-CAS Complexes
2001
Cancer driver mutations in protein kinase genes
2008
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Deciphering the late steps in the biosynthesis of the anti‐tumour indolocarbazole staurosporine: sugar donor substrate flexibility of the StaG glycosyltransferase
2005
Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis
2005
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)
2001
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors
1999
Protein kinases — the major drug targets of the twenty-first century?
2002 Standout
Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors
2004
Neonatal Lethality in Mice Deficient in XCE, a Novel Member of the Endothelin-converting Enzyme and Neutral Endopeptidase Family
1999
Synthesis of new aza-analogs of staurosporine, K-252a and rebeccamycin by nucleophilic opening of C2-symmetric bis-aziridines
2008
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
2004
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
Designing bisubstrate analog inhibitors for protein kinases
2002
A Role for the Segment Polarity Gene shaggy/GSK-3 in the Drosophila Circadian Clock
2001 StandoutNobel
The Conformational Plasticity of Protein Kinases
2002
Inositol trisphosphate and calcium signalling
1993 StandoutNature
CASK Functions as a Mg2+-Independent Neurexin Kinase
2008 StandoutNobel
The PtdIns(3,4)P2 phosphatase INPP4A is a suppressor of excitotoxic neuronal death
2010 StandoutNatureNobel
Revealing the world of RNA interference
2004 StandoutNatureNobel
Signalling from adenosine receptors to mitogen-activated protein kinases
2003
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
2003 Standout
Mitogen‐activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment
2006
Interpreting cDNA sequences: Some insights from studies on translation
1996
The synthesis of bioactive indolocarbazoles related to K-252a
2005
Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3β constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines
2006
Matrix Elasticity Directs Stem Cell Lineage Specification
2006 Standout
c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines
2000
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
2005
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
2007
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
Benzannulation reactions of Fischer carbene complexes for the synthesis of indolocarbazoles
2001
Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976
1993 Standout
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na + channels
2004 StandoutNobel
The mouse and human genes encoding the recognition component of the N-end rule pathway
1998 StandoutNobel
Roles of the Two Drosophila CRYPTOCHROME Structural Domains in Circadian Photoreception
2004 StandoutScienceNobel
Direct catalytic asymmetric Mannich-type reaction of unmodified ketones utilizing the cooperation of an AlLibis(binaphthoxide) complex and La(OTf)3·nH2O
1999
Novel 3‘,6‘-Anhydro and N12,N13-Bridged Glycosylated Fluoroindolo[2,3-a]carbazoles as Topoisomerase I Inhibitors. Fluorine as a Leaving Group from sp3Carbon
2005
Indium-Catalyzed Annulation of 2-Aryl- and 2-Heteroarylindoles with Propargyl Ethers: Concise Synthesis and Photophysical Properties of Diverse Aryl- and Heteroaryl-Annulated[a]carbazoles
2008
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
2002
Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor
1999
Synthesis and Function of 3-Phosphorylated Inositol Lipids
2001 Standout
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
2002
Tyrosine Kinases as Targets for Cancer Therapy
2005
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000
The Protein Kinase Complement of the Human Genome
2002 StandoutScience
Ramshackle (Brwd3) promotes light-induced ubiquitylation of Drosophila Cryptochrome by DDB1-CUL4-ROC1 E3 ligase complex
2013 StandoutNobel
Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles1
1996
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Dissecting Temporal and Spatial Control of Cytokinesis with a Myosin II Inhibitor
2003 Science
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids
2012 Standout
Recent developments in the synthesis of biologically active indole alkaloids
2002
Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor
1997
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
2000
Reaction mechanism of Drosophila cryptochrome
2010 StandoutNobel
Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of Distal Arthrogryposis
2013 StandoutNobel
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
Open Analogues of Arcyriaflavin A. Synthesis through Diels−Alder Reaction between Maleimides and 1-Aryl-3-tert-butyldimethylsiloxy-1,3-butadienes
2000
ZHD-0501, a novel naturally occurring staurosporine analog from Actinomadura sp. 007
2005
Synthesis of Aryl- and Heteroaryl[a]pyrrolo[3,4-c]carbazoles
2003
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
2005
Regiocontrolled Synthesis of the Antitumor Antibiotic AT2433-A1
2000
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
2000
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
2000 StandoutScience
Regioselective imide reduction : An issue in the total synthesis of staurosporine
1994
Synthesis of granulatimide bis-imide analogues
2005
Rebeccamycin analogues as anti-cancer agents
2003
Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells
2001 StandoutNobel
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines
2000
Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors
1999
Comparative Analysis of Mutant Tyrosine Kinase Chemical Rescue
2009 StandoutNobel
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Molecular mechanisms of resistance of leukemia to imatinib mesylate
2003
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
2000
Synthesis of a staurosporine analogue possessing a 7-azaindole unit instead of an indole moiety
2004
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
2002
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor.
1992
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
First synthesis of symmetrical and non-symmetrical aza indolocarbazoles derivatives
2002
Asymmetric Enamine Catalysis
2007 StandoutNobel
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
2004 Standout
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
2002 Standout
Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
A Role for the Proteasome in the Light Response of the Timeless Clock Protein
1999 Science
Synthesis of bridged aza-rebeccamycin analogues
2005
A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective
2021
Works of Thomas Meyer being referenced
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.
1990
Expression and partial characterization of rat protein kinase C‐δ and protein kinase C‐ξ in insect cells using recombinant baculovirus
1992
Molecular characterization of human and bovine endothelin converting enzyme (ECE‐1)
1994
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
2003
Different Susceptibility of Protein Kinases to Staurosporine Inhibition
1995
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
2002
Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors
2002
The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation
2005
Sulfonylbenzoyl-nitrostyrenes: Potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase
1991
Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases
2004
Inhibitors of Protein KinasesCGP 41251, a Protein Kinase Inhibitor with Potential as an Anticancer Agent
1999
Selective GRB2 SH2 inhibitors as anti-Ras therapy
1999
Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities
2004
Imatinib: a selective tyrosine kinase inhibitor
2002
Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin
1998
A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C
2002
[(Alkylamino)methyl]acrylophenones: Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase
1995
Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase
1994
Further Minor Metabolites of Staurosporine Produced by a Streptomyces longisporofiavus Strain.
1996
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
1995
In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase
2004
AEE788
2004
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
1997
Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C
1994
Synthesis, Mode of Action, and Biological Activities of Rebeccamycin Bromo Derivatives
1999
4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase
1996
Syntheses and Biological Evaluation of Indolocarbazoles, Analogues of Rebeccamycin, Modified at the Imide Heterocycle
1998
Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines
1997
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
1996 Standout
Structure−Activity Relationships in a Series of Substituted Indolocarbazoles: Topoisomerase I and Protein Kinase C Inhibition and Antitumoral and Antimicrobial Properties
1996
Syntheses and Biological Activities (Topoisomerase Inhibition and Antitumor and Antimicrobial Properties) of Rebeccamycin Analogues Bearing Modified Sugar Moieties and Substituted on the Imide Nitrogen with a Methyl Group
1997
Syntheses and Biological Activities of Rebeccamycin Analogues. Introduction of a Halogenoacetyl Substituent
1999
Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors
1996